Article Abstract:
Developments in psychopharmacology and advances in research in the neuropathology of schizophrenia have resulted in new approaches to anti- psychotic drug development. Proposed potential antipsychotic treatments with less extrapyramidal side-effects include sulpiride, which is a dopamine D2-selective blocker and clozapine, which is a D1 and 5-HT2 receptors blocker. Other possible neurochemical etiologies of schizophrenia which may be of value in antipsychotic drug development include that of 5-HT3 receptors, noradrenaline systems, sigma sites, dopamine D3 and D4 receptors and glutamate systems.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Pierre Laduron endorses the use of sumatriptan as a presynaptically acting drug for modulating transmitter release in the treatment of degenerative disorders and schizophrenia. However, the compound has been found to cause tachycardia unlike similar drugs such as amisulpride. Amisulpride works by blocking dopamine D2 and D3 autoreceptors that control dopamine release and synthesis at the presynaptic level. Clinical trials show the effectiveness of the drug on the symptoms of schizophrenia.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Langer et al., used the antidepressant mirtazepine and the neuroleptic amisulpride to demonstrate the importance of presynaptic receptors in drug development. However, the mechanism of action of these drugs at the presynaptic level is questionable. Sumatripan and other related compounds are more appropriate examples of new drugs that act presynaptically. These compounds produce fewer side effects and are more efficient in the treatment of schizophrenia and degenerative disorders.
User Contributions:
Comment about this article or add new information about this topic: